Literature DB >> 16710326

Advances in tuberculosis vaccine strategies.

Yasir A W Skeiky1, Jerald C Sadoff.   

Abstract

Tuberculosis (TB), an ancient human scourge, is a growing health problem in the developing world. Approximately two million deaths each year are caused by TB, which is the leading cause of death in HIV-infected individuals. Clearly, an improved TB vaccine is desperately needed. Heterologous prime-boost regimens probably represent the best hope for an improved vaccine regimen to prevent TB. This first generation of new vaccines might also complement drug treatment regimens and be effective against reactivation of TB from the latent state, which would significantly enhance their usefulness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710326     DOI: 10.1038/nrmicro1419

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  97 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

3.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

4.  Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Authors:  Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

5.  MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice.

Authors:  Shihoko Komine-Aizawa; Jiansheng Jiang; Satoru Mizuno; Satoshi Hayakawa; Kazuhiro Matsuo; Lisa F Boyd; David H Margulies; Mitsuo Honda
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

6.  Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles.

Authors:  Chenchen Wang; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2010-03-26       Impact factor: 3.246

7.  The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells.

Authors:  Avi-Hai Hovav; Michael W Panas; Christa E Osuna; Mark J Cayabyab; Patrick Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

8.  Synthesis and immunogenicity of the Mycobacterium tuberculosis arabinomannan-CRM197 conjugate.

Authors:  Yunsong Chang; Xin Meng; Yaxin Li; Jianmei Liang; Tingshen Li; Demei Meng; Tao Zhu; Peng Yu
Journal:  Medchemcomm       Date:  2019-04-02       Impact factor: 3.597

9.  Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis.

Authors:  Nicholas P West; Teresa M Wozniak; Jesus Valenzuela; Carl G Feng; Alan Sher; Jose M C Ribeiro; Warwick J Britton
Journal:  Vaccine       Date:  2008-05-23       Impact factor: 3.641

10.  Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques.

Authors:  Myrna C Bonaldo; Mauricio A Martins; Richard Rudersdorf; Philip A Mudd; Jonah B Sacha; Shari M Piaskowski; Patrícia C Costa Neves; Marlon G Veloso de Santana; Lara Vojnov; Saverio Capuano; Eva G Rakasz; Nancy A Wilson; John Fulkerson; Jerald C Sadoff; David I Watkins; Ricardo Galler
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.